2008-05-12 13:28:02 -
www.biolinerx.com - BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, announced today that Yuri Shoshan, VP Finance and Corporate Development, will present a company overview at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20, 2008 at 11:20 AM CEST (5:20 AM EDT) at Le Meridien Beach Plaza Hotel in Monte Carlo,
Monaco.
A live webcast of the presentation may be accessed under the Events section of the Company's website, www.BioLineRx.com. A replay of the presentation will be available at this location for 90 days following the presentation.
About BioLineRx
BioLineRx, a clinical stage drug development company traded on the Tel Aviv Stock Exchange (TASE:BLRX), is dedicated to building a robust pipeline of promising therapeutics for unmet medical needs. The Company's leading programs are BL-1020 for the treatment of schizophrenia, which has recently completed a Phase 2a trial and is about to begin its Phase 2b trial shortly, and BL-1040 for the treatment of damaged heart tissue post-myocardial infarction, which is undergoing a Phase 1/2 study. Additional products under development include compounds for the treatment of cancer and CNS, cardiovascular, metabolic, infectious and autoimmune diseases.
BioLineRx advances projects from early stage discovery and lead generation to advanced clinical trials. BioLineRx partners with researchers, universities and biotech companies to further the development of promising compounds. The Company was founded in 2003 by leaders in the Israeli life science arena including Teva Pharmaceuticals Ltd., venture capital firms Giza Venture Capital and Pitango Venture Capital, and Hadasit, the technology transfer company of Hadassah Hospital and the Jerusalem Development Authority. For more information, please visit www.biolinerx.com.
BioLineRx Ltd.
Yuri Shoshan, +972-2-548-9100
VP Finance and Corporate Development
yuri@biolinerx.com
Tsipi Haitovsky, +972-52-598-9892
Media Liaison
tsipih@biolinerx.com
or
Stern Investor Relations, Inc.
Stephanie Baritz, 212-362-1200
stephanie@sternir.com 
